Table 2

Comparative results of plasma tumor DNA, CK19 mRNA, and immunocytochemistry in patients with locally advanced or metastatic breast cancer

Patient no.Sites of metastasesPlasma DNA resultCK19 QPCRaImmunocytochemistryTreatment
1Bo/Li/LNbMI1:200 (+)NegNil
2Li/LNNAD1:40 (+)NegNil
3Bo/LiMI1:1600 (−)NegNil
4Bo/LiLOH1:800 (+)NegNil
5Sk/LNLOH1:200 (+)PosNil
6Bo/Li/LNNAD1:120 (+)PosNil
7BrNAD1:2500 (−)NegNil
8Bo/LuLOH1:1000 (−)NegNil
9Bo/LiMI1:100 (+)NegNil
10Li/Lu/LNNAD1:400 (+)NegMegace
11Bo/Li/BrNAD1:400 (+)NegMitozantrone, methotrexate
12Bo/Lu/BrNAD1:600 (+)PosDocetaxel
13BoNAD1:1300 (−)NegTamoxifen
14BoMI1:1300 (−)NegArimidex
15LNNAD1:400 (+)NegTamoxifen
16LNNAD1:800 (+)NegFormestane
17BoNAD1:800 (+)Neg5-fluorouracil, epirubicin, cyclophosphamide
18BoNAD1:1700 (−)NegArimidex
  • a QPCR for CK19: +, ABL mRNA ratio greater than normal; −, ABL mRNA ratio less than normal.

  • b Bo, bone; Li, liver; LN, lymph node; Neg, negative; NAD, no alteration detected; Sk, skin; Pos, positive; Br, breast; Lu, lung.